Cyclic reoccurrence of cycle symptoms and their impact on perceived sport performance, perceived exertion, and training participation in women with an eumenorrheic menstrual cycle and woman under hormonel contraception.
Conditions
Interventions
Group 1: Women with a eumenorrheic menstrual cycle (menstrual cycle length of 21-35 days with more than 9 consecutive periods per year)
Group 2: Women using combined oral contraceptives (containing et
Sponsors
Deutsche Sporthochschule Köln
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: General: Non-smoker, no chronic or acute injuries, trained (exercises more than 3 times a week) (1) Women with an eumenorrheic menstrual cycle or who use a copper-based contraceptive, such as an IUD, copper chain, or copper ball. -> Regular cycle of 21–35 days, at least 9 consecutive periods per year, no hormonal contraception for more than 3 months (2) Women taking the combined oral contraceptive pill. -> For more than 3 months, a combination of ethinyl estradiol and levonorgestrel, with a 21-day intake phase and a 7-day intake break (3) Women taking the progestin-only pill. -> For more than 3 months, containing desogestrel, with a 28-day intake phase and no intake break (4) Women using the hormonal IUD. -> For more than 3 months, containing levonorgestrel (5) Women diagnosed with a menstrual cycle disorder.
Exclusion criteria
Exclusion criteria: see inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WHAT: (a) the cyclic reoccurrence of the type and intensity of negative cycle symptoms; (b) the consistency of their impact on perceived sport performance, perceived exertion, and training participation; and (c) differences in (a) and (b) between these groups. WHEN: daily over 4 consecutive cycles HOW: daily short online questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondray: WHAT: As a secondary aim, these objectives will additionally be examined (d) with regard to positive cycle symptoms, (e) in women diagnosed with a MD, and (f) in association to an individual hormonal profile. WHEN: (d) and (e) daily over 4 consecutive cycles; (f) once per cycle at a specific timepoint HOW: (d) and (e) daily with a short online questionnaire; (f) blood collection Third: WHAT: participants’ experience and perception of the conducted symptom-based cycle monitoring during the study period WHEN: directly before and after the monitoring phase HOW: selfcreated questionnaire | — |
Countries
Germany
Contacts
Public ContactFranziska Moser
Deutsche Sporthochschule Köln
Outcome results
None listed